Codexis (CDXS) Competitors

Regulus Therapeutics (NASDAQ:RGLS) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.

Do analysts recommend RGLS or CDXS?

Regulus Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 4.94%. Codexis has a consensus target price of $11.00, suggesting a potential upside of 382.46%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Regulus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regulus Therapeutics	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Codexis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer RGLS or CDXS?

Regulus Therapeutics received 143 more outperform votes than Codexis when rated by MarketBeat users. Likewise, 63.33% of users gave Regulus Therapeutics an outperform vote while only 61.36% of users gave Codexis an outperform vote.

Company	Underperform	Outperform
Regulus Therapeutics	Outperform Votes 494 63.33%	Underperform Votes 286 36.67%
Codexis	Outperform Votes 351 61.36%	Underperform Votes 221 38.64%

Which has more risk and volatility, RGLS or CDXS?

Regulus Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Does the media refer more to RGLS or CDXS?

In the previous week, Codexis had 1 more articles in the media than Regulus Therapeutics. MarketBeat recorded 6 mentions for Codexis and 5 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 1.29 beat Codexis' score of 1.13 indicating that Regulus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regulus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RGLS or CDXS more profitable?

Regulus Therapeutics has a net margin of 0.00% compared to Codexis' net margin of -96.35%. Regulus Therapeutics' return on equity of -53.07% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regulus Therapeutics	N/A	-53.07%	-48.58%
Codexis	-96.35%	-71.56%	-38.00%

Which has preferable valuation and earnings, RGLS or CDXS?

Regulus Therapeutics has higher earnings, but lower revenue than Codexis. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regulus Therapeutics	N/A	N/A	-$30.04M	-$0.73	-11.10
Codexis	$49.82M	3.79	-$76.24M	-$0.99	-2.30

Do insiders & institutionals have more ownership in RGLS or CDXS?

92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by company insiders. Comparatively, 2.1% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Regulus Therapeutics beats Codexis on 10 of the 17 factors compared between the two stocks.